EAHAD 2016: Highlight interviews

February 10, 2016

  • Share this post:

Highlight 1: Von Willebrand Disease

– Carolyn Millar, MD, Hammersmith Hospital, London: The necessity of VWD subclassification

– Vuokko Jokela, MD, Helsinki University Central Hospital: Impact of platelet function on clinical phenotypes in Von Willebrand Disease: re-evaluation of 83 patient with historical diagnosis

– Lucia Rugeri, MD, Hôpital Cardiologique, Lyon: Genotyping might help therapeutic decision making in patients with Von Willebrand Disease type 2B (VWD2B)

Click here to go to this highlight


Highlight 2: Hemophilia A

– Elena Santagostino, MD PhD, Maggiore Hospital Policlinico, Milan: TGA for testing of hemostatic effectiveness of fVIII concentrates in patients with Hemophilia A and inhibitors: in vitro results from the predicTGA study

– Prof. Cédric Hermans, MD, St-Luc University Hospital, Brussels: Updates on the SIPPET, FranceCoag and RODIN studies: the relationship between specific FVIII concentrate and inhibitor formation

– Katharina Holstein, MD, University Medical Centre, Hamburg: Expression and release of platelet protein disulfide isomerase (PDI) is increased in patients with hemophilia A

– Prof. Karin Fijnvandraat, MD, Academisch Medisch Centrum, Amsterdam: Case report – Multidisciplinary approach, treatment of inhibitors with ITI

Click here to go to this highlight


Highlight 3: Musculoskeletale complicaties

– Prof. Alok Srivastava, MD, Christian Medical College, Vellore: Low dose prophylaxis and treatment of joint inflammation caused by joint bleeds

– Mehdi Osooli, M.Sc., Lund University: Joint outcomes in mild hemophilia: a register based study

– Björn Rosengren, MD PhD, Skåne University Hospital, Malmö: Managing osteoporosis in hemophilia patients

Click here to go to this highlight



Prof. Karin Fijnvandraat, AMC Amsterdam

Dr. Marjon Cnossen, Erasmus MC Rotterdam

Prof. Karina Meijer, UMCG Groningen


The EAHAD 2016 highlights are financially supported by Bayer B.V.